ADMA Biologics
ADMA
$6.81
Share price
1.04%
Change (1 day)
99.12%
Change (1 year)
Categories
ADMA Biologics (ADMA) - Cash on Hand
Cash on Hand as of December 2023 : $51.35 M
According to ADMA Biologics
's latest financial reports the company has $51.35 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
ADMA Biologics - Cash on Hand chart (from 2010 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $51.35 M | -40.65% |
| 2022-12-31 | $86.52 M | 69.36% |
| 2021-12-31 | $51.08 M | -8.64% |
| 2020-12-31 | $55.92 M | 109.03% |
| 2019-12-31 | $26.75 M | 17.57% |
| 2018-12-31 | $22.75 M | -47.21% |
| 2017-12-31 | $43.1 M | 181.66% |
| 2016-12-31 | $15.3 M | -8.95% |
| 2015-12-31 | $16.8 M | -23.08% |
| 2014-12-31 | $21.85 M | -24.87% |
| 2013-12-31 | $29.08 M | 132.02% |
| 2012-12-31 | $12.53 M | |
| 2011-06-30 | $0 M | -29.14% |
| 2010-06-30 | $0.01 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | $0.75 B | 1,363.08% | 🇺🇸 USA |
 Novavax NVAX | $0.56 B | 1,007.07% | 🇺🇸 USA |
 Cel-Sci
CVM | $3.24 M | -93.69% | 🇺🇸 USA |